W
Walhan Alshaer
Researcher at University of Jordan
Publications - 81
Citations - 1524
Walhan Alshaer is an academic researcher from University of Jordan. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 12, co-authored 51 publications receiving 640 citations. Previous affiliations of Walhan Alshaer include Université Paris-Saclay & Max Delbrück Center for Molecular Medicine.
Papers
More filters
Journal ArticleDOI
Aptamers Chemistry: Chemical Modifications and Conjugation Strategies.
Fadwa Odeh,Hamdi Nsairat,Walhan Alshaer,Mohammad A. Ismail,Ezaldeen Esawi,Bara’a M. Qaqish,Abeer Al Bawab,Said I. Ismail,Said I. Ismail +8 more
TL;DR: Aptamers are short single-stranded RNA or DNA oligonucleotides capable of folding into complex 3D structures, enabling them to bind to a large variety of targets ranging from small ions to an entire organism, and they are superior regarding a longer shelf life, simple production and chemical modification.
Journal ArticleDOI
Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells
TL;DR: 2'-F-pyrimidine-containing RNA aptamer (Apt1), previously selected against CD44, was successfully conjugated to the surface of PEGylated liposomes using the thiol-maleimide click reaction, demonstrating a promising potency of Apt1-Lip as a specific drug delivery system.
Journal ArticleDOI
Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2.
Ma'mon M. Hatmal,Walhan Alshaer,Mohammad A. I. Al-Hatamleh,Malik Hatmal,Othman Smadi,Mutasem O. Taha,Ayman Oweida,Jennifer C. Boer,Rohimah Mohamud,Magdalena Plebanski +9 more
TL;DR: This review comprehensively addresses in detail the variations in S protein, its receptor-binding characteristics and detailed structural interactions, the process of cleavage involved in priming, as well as other differences between coronaviruses.
Journal ArticleDOI
Aptamer-guided nanomedicines for anticancer drug delivery
TL;DR: The current advances in the use of aptamers as targeting moieties for the delivery of therapeutic and imaging agents to tumors by conjugation to organic and inorganic nanocarriers are described.
Journal ArticleDOI
Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model.
Walhan Alshaer,Hervé Hillaireau,Juliette Vergnaud,Simona Mura,Claudine Deloménie,Félix Sauvage,Said I. Ismail,Elias Fattal +7 more
TL;DR: A liposome‐based siRNA delivery system with a core composed of siRNA:protamine complex and a shell designed for the active targeting of CD44‐expressing cells using for the first time the anti‐CD44 aptamer (named Apt1) as targeting ligand is described.